



Global landscape of COVID-19 research: a visualization analysis of randomized clinical trials

Sa'ed H. Zyoud^{1,2}

Received: 16 May 2023 / Accepted: 18 December 2023 / Published online: 22 January 2024
© The Author(s) 2024

Abstract

The emergence of COVID-19 in 2019 has resulted in a significant global health crisis. Consequently, extensive research was published to understand and mitigate the disease. In particular, randomized controlled trials (RCTs) have been considered the benchmark for assessing the efficacy and safety of interventions. Hence, the present study strives to present a comprehensive overview of the global research landscape pertaining to RCTs and COVID-19. A bibliometric analysis was performed using the Scopus database. The search parameters included articles published from 2020 to 2022 using keywords specifically related to COVID-19 and RCTs. The data were analyzed using various bibliometric indicators. The volume of publications, contributions of countries and institutions, funding agencies, active journals, citation analysis, co-occurrence analysis, and future research direction analysis were specifically analyzed. A total of 223,480 research articles concerning COVID-19 were published, with 3,727 of them related to RCTs and COVID-19. The ten most productive countries collectively produced 75.8% of the documents, with the United States leading the way by contributing 31.77%, followed by the UK with 14.03% ($n=523$), China with 12.96% ($n=483$) and Canada with 7.16% ($n=267$). *Trials* ($n=173$, 4.64%), *BMJ Open* ($n=81$, 2.17%), *PLOS One* ($n=73$, 1.96%) and *JAMA Network Open* ($n=53$, 1.42%) were the most active journals in publishing articles related to COVID-19 RCTs. The co-occurrence analysis identified four clusters of research areas: the safety and effectiveness of COVID-19 vaccines, mental health strategies to cope with the impact of the pandemic, the use of monoclonal antibodies to treat patients with COVID-19, and systematic reviews and meta-analyses of COVID-19 research. This paper offers a detailed examination of the global research environment pertaining to RCTs and their use in the context of the COVID-19 pandemic. The comprehensive body of research findings was found to have been generated by the collaborative efforts of multiple countries, institutions, and funding organizations. The predominant research areas encompassed COVID-19 vaccines, strategies for mental health, monoclonal antibodies, and systematic reviews. This information has the potential to aid researchers, policymakers, and funders in discerning areas of weakness and establishing areas of priority.

Keywords Bibliometric · COVID-19 · Visualization · VOSviewer · Scopus · Randomized controlled trials

Abbreviations

COVID-19	Coronavirus disease 2019
RCTs	Randomized controlled trials
FDA	Food and Drug Administration
WHO	World Health Organization
MeSH	Medical Subject Headings

Background

The COVID-19 pandemic, which emerged in 2019, has rapidly expanded throughout numerous countries worldwide, resulting in a substantial public health crisis with effects at an international level [1]. On May 3, 2023, the epidemic had a significant impact, resulting in over 765 million confirmed cases and a mortality rate of 6.92 million [2].

The COVID-19 pandemic has prompted researchers, regulators, and policymakers to respond promptly by finding strategies for preventing the pandemic [3]. Nevertheless, the scientific community has faced challenges in generating dependable data to inform and direct these strategies. The delays experienced can be attributed, at least in part, to the intricacies involved in conducting clinical trials amidst

✉ Sa'ed H. Zyoud
saedzyoud@yahoo.com; saedzyoud@najah.edu

¹ Department of Clinical and Community Pharmacy, College of Medicine and Health Sciences, An-Najah National University, Nablus 44839, Palestine

² Clinical Research Centre, An-Najah National University Hospital, Nablus 44839, Palestine

a pandemic. These complexities encompass challenges related to participant recruitment and the assurance of their safety [4]. Furthermore, the global pandemic has exerted immense pressure on healthcare systems and economics, thereby impeding the progress of developing and evaluating novel medical interventions. Given the challenges mentioned above, the Food and Drug Administration (FDA) has formulated regulatory guidelines for implementing clinical studies in the context of pandemics [5]. Notably, regulatory measures have exhibited more flexibility throughout the current period. However, achieving an appropriate balance in resource allocation, including financial and human resources, is crucial for studies pertaining to COVID-19 and non-COVID-19 subjects.

The COVID-19 pandemic has highlighted the need for well-designed randomized clinical trials (RCTs). Several studies have shown uncertain outcomes, and most COVID-19 clinical trials have been undertaken without adequate methods or planning [4, 6–9]. These trials evaluate herbal preparations, invasive medical procedures, vaccines, and experimental stem cell therapy in patients ranging from pre-exposure prophylaxis to critically ill hospitalized patients. Few trials have examined pre- or post-exposure to COVID-19, and most have focused on hospitalized patients [10–13]. More than 100 therapeutic compounds are being studied, although many are repurposed medications such as hydroxychloroquine and lopinavir-ritonavir for COVID-19. Most of these studies typically enroll fewer than 100 participants for experimental intervention, resulting in overlap and duplication [4, 9, 14].

The global impact of the COVID-19 pandemic has been significant, highlighting the crucial necessity for new vaccines and treatments [15]. Despite the lack of known therapy, researchers and medical professionals have worked tirelessly to conduct clinical trials and discover novel treatments for the disease [16, 17]. As evident from the vast array of medical research, with more than 300,000 articles currently available in PubMed, the epidemic has spurred a wealth of investigations on various aspects of the virus [18].

Randomized clinical trials are crucial in advancing the understanding and development of COVID-19 treatments. These trials offer a rigorous and controlled approach to evaluating the safety and effectiveness of interventions [19, 20], making them the most reliable method for evaluating health interventions. The design of RCTs is structured to minimize bias, which is why their results are considered the gold standard in medical research, and their impact on medical care is unmatched compared to other study designs [21]. As evidence-based medicine gains traction, the number and scope of RCTs are increasing exponentially, expanding their utility beyond their original purpose of testing pharmaceutical drugs, including evaluating treatments, devices, and diagnostics.

Despite the vast body of COVID-19 research, a comprehensive understanding of the global research landscape requires a comprehensive analysis of RCTs. A comprehensive summary of the current status of COVID-19 RCTs is not yet available, although numerous studies have focused on specific therapies. Consequently, the purpose of this study is to provide a comprehensive outline of COVID-19 investigation by conducting a review of the literature, identifying potential research gaps, and highlighting the most crucial topics. The purpose of this study is to enhance our understanding of the global research landscape pertaining to COVID-19 through a thorough examination of COVID-19 RCTs using literature analysis and visual aids.

Bibliometric analysis has gained widespread acceptance as a quantitative and qualitative method for evaluating global research contributions within a particular literary field [22–24]. Bibliometric research has garnered significant interest due to its efficacy in forecasting research trends in both established and emerging fields [25, 26]. This particular analytic method has been extensively employed across several academic fields [27–34], highlighting its effectiveness in supporting the process of decision-making. In recent years, there has been a notable surge in scholarly investigations focused on scientometric and bibliometric analyses pertaining to the COVID-19 pandemic [35–40]. The primary outcome of this study is to facilitate evidence-based decision-making among academics, policymakers, and medical practitioners by identifying potential areas of research advancement and alternative treatment options within the domain of COVID-19. This work has the potential to make a significant contribution to worldwide endeavors aimed at minimizing the impact of the COVID-19 pandemic.

Methods

Study design

Using bibliometric tools, a descriptive cross-sectional study was conducted on publications related to COVID-19 RCTs.

Data source

Scopus is a well-known abstracting and citation database owned by Elsevier and used to search for published works. It features advanced scientific search engines and databases to obtain library data, making it a popular choice among academics. Unlike databases such as Web of Science, PubMed, and Google Scholar, Scopus is widely acknowledged as the leading quality-oriented database globally. It offers a more extensive and standardized repository of scientific literature, facilitating access to research work in diverse fields of inquiry [41, 42]. However, despite commendable endeavors

by both WoS and Scopus to extend their inclusiveness, particularly in the last decade, the same applies to incorporating non-English language materials and regionally significant sources. Consequently, the primary biases toward an overabundance of English-language content, an uneven portrayal of nations, and an insufficient representation of literature in the social sciences and humanities persist as key constraints within these data repositories. However, numerous investigations have shown that Scopus delivers more extensive coverage in terms of both publications and citations in diverse fields and document categories. Additionally, it presents a more comprehensive rendering of non-English and localized literature. As a result, Scopus emerges as a more favorable selection for undertaking endeavors in the sphere of arts and humanities, especially when engaging in inventive and domestically focused research. This is particularly relevant when evaluating the caliber of sources in these domains, as WoS lacks impact metrics for such materials [43–46].

The author performed a bibliometric analysis using the SciVerse Scopus database. This analysis differs from systematic and scoping reviews [47–50] because it uses a comprehensive database to retrieve, review and visualize data, including information on citations and research collaboration. Systematic reviews can be broadly characterized as a form of research synthesis undertaken by specialized review groups. These groups aim to locate and retrieve global evidence relevant to specific questions [51–54]. They then assess and amalgamate the results of this inquiry to guide practice, policy, and, in some instances, future investigations [55]. In contrast, scoping reviews present an optimal approach to determine the extent and inclusiveness of a body of literature focused on a designated subject. They distinctly indicate the quantity of available literature and studies and provide a comprehensive (either broad or detailed) overview of their subject matter [48, 56–58]. Scoping reviews play a pivotal role in pinpointing voids within the literature, discerning the need for further research, and initially outlining the contours of the topic. They are particularly valuable for examining emerging evidence, especially when the potential for more specific questions in a more precise systematic review remains unclear. These reviews can delineate the types of evidence that address and influence practices within the field and the methodologies employed in the research [55].

Search strategy

A detailed search was conducted using the Scopus database to gather pertinent information on COVID-19 RCTs. Publications issued from January 1, 2020, to December 31, 2022, had restrictions in the search conducted. To ensure accuracy and avoid any potential biases that may have been caused by constant updates and changes to the database, all

relevant articles were retrieved and exported within a single day, specifically on April 23, 2023. The approach to data collection was precise and methodical, and an advanced search technique was utilized, which allowed filtering through a vast amount of literature to extract only the most relevant studies on the subject matter. By incorporating various keywords and phrases related to COVID-19 RCTs, a comprehensive search strategy was developed. Data for this study were retrieved using the following strategy:

- *Step 1* To achieve the goals of the study, COVID-19-associated terminology was entered into the Scopus research engine. This terminology was derived from various sources, including PubMed Medical Subject Headings (MeSH) and previous systematic and meta-analyses related to COVID-19 [59–62], as well as bibliometric studies focusing on COVID-19 [63–68]. All selected terms were then placed in the "Article Title" section.
- *Step 2* Subsequently, the documents found in the first step were narrowed down to only include those with the phrase "randomized controlled trials" and related terms in their titles or abstracts. The relevant terms for the randomized controlled trials were obtained from PubMed Medical Subject Headings (MeSH), as well as previous systematic reviews and meta-analyses on COVID-19 that involved RCTs [69–72].
- *Step 3* The scope of the retrieved documents was restricted to include only primary research articles while ignoring other forms of text, such as editorials, letters, and proceedings.

Validation of the search strategy

The precision of the search strategy and the absence of bias were confirmed by two volunteers (S. A. and A. A.) by reviewing the titles and abstracts of the top 200 cited articles in the retrieved dataset. The retrieved document list from Scopus was subjected to systematic random sampling, where 10% of the list was taken. Every 10th, 20th, 30th, 40th document, and so on up to the end of the retrieved document list, was scrutinized by evaluating their titles and abstracts to avoid false positive outcomes. The research strategy was continuously refined until a completely accurate set of randomly selected outcomes was obtained. The research productivity of 20 active authors in the field was examined to validate the absence of false negative or missing results. A Spearman correlation test was used to compare the results obtained from the research strategy and the authors. The study revealed a strong and significant correlation ($p < 0.001$; $r = 0.958$) between the two sets of results, indicating the high level of validity of the research strategy. Notably, Sweileh et al. previously employed this validation approach [73–75].

Bibliometric indicators

This research involved the examination of several bibliometric indicators, namely, (1) the total count of published works; (2) the impact factors of the top ten journals that had the most substantial influence; (3) the ten most frequently cited articles; (4) the research output levels of the top ten countries; (5) the research output levels of the top ten institutes; (6) the top ten funding agencies that supported research activities; and (7) citation patterns and the *h*-index.

Data analysis and visualization

The dataset resulting from the final search query was extracted from Scopus as a CSV file. This file was utilized for both basic bibliometric analysis and advanced mapping techniques. To accomplish this, the CSV file containing the entire literature corpus was uploaded to VOSviewer version 1.6.19, a specialized online program designed to create visual maps based on user-defined queries. The interpretation of maps generated by the program is dependent on various factors, such as node size, color, line thickness, and proximity to other nodes [76, 77]. For instance, the size in a term map is determined by the frequency of occurrence of that term. In contrast, nodes of similar color represent a cluster that signifies a particular topic or research theme. To determine the main themes in the literature corpus, the most common terms in titles/abstracts with at least 100 appearances per term were mapped. VOSviewer also provides an overlay visualization option highlighting the most recent terms in yellow. The overlay visualization was based on the occurrence and average publication scores of the terms per year. When mapping countries, node size is proportional to the number of publications with joint authorship. Therefore, a larger node size indicates a higher degree of international collaboration.

Results

Volume of publications

Throughout the data collection period from 2020 to 2022, 223,480 research articles concerning COVID-19 were published. When narrowing the search down to articles related to COVID-19 RCTs, Scopus was able to pinpoint 3727 relevant articles. Among these 3727 examined documents, 638 (17.12%) were published in 2020, 1358 (36.44%) in 2021, and 1731 (46.44%) in 2022.

Active countries

The production of research related to COVID-19 RCTs was a collaborative effort among 127 countries. Table 1 highlights the top ten countries that were most productive in this regard. The analysis reveals that these ten countries collectively produced 75.8% of the documents, with the US leading the way by contributing 31.77%, followed by the UK with 14.03% ($n = 523$), China with 12.96% ($n = 483$) and Canada with 7.16% ($n = 267$). Furthermore, a network of countries was formed as depicted in Fig. 1, with each node representing a distinct country that produced at least 50 articles. The links between the nodes indicate collaborative relationships between countries. The USA and the UK emerged as the primary collaborators and have the strongest alliance ties in research with other countries.

Active institutions/organizations

Table 2 presents a list of the top ten institutions that have been actively involved in producing research publications on RCTs related to COVID-19. It is evident from the analysis that these institutions collectively contributed to 15.88% of the total documents published in this area. The leading position has been occupied by *Harvard Medical School*, which has produced 129 documents, accounting for 3.46% of the total publications. This is followed by the *University of Oxford* with 123 publications (3.30%), *Imperial College London* with 95 publications (2.55%), and the *University of Toronto* with 90 publications (2.41%). The majority of active institutions were based in the UK, with four institutions represented, followed by the United States with two institutions and one institution each from Canada, France, Brazil, and Iran.

Table 1 Publications related to COVID-19 RCTs from the ten most productive countries/regions

Ranking	Country	Number of documents	%
1st	United States	1184	31.77
2nd	United Kingdom	523	14.03
3rd	China	483	12.96
4th	Canada	267	7.16
5th	India	252	6.76
6th	Spain	247	6.63
7th	Iran	235	6.31
8th	Italy	232	6.22
9th	Brazil	222	5.96
10th	Germany	203	5.45

Fig. 1 A network visualization map illustrating coauthorship collaborations among countries with more than 50 publications: of the 127 countries published in this field, 28 met the criterion. The size of the nodes on the map represents the number of publications by each country




Table 2 Top ten institutions publishing COVID-19 RCTs

Ranking	Institute	Country	<i>n</i>	%
1st	Harvard Medical School	USA	129	3.46
2nd	University of Oxford	UK	123	3.30
3rd	Imperial College London	UK	95	2.55
4th	University of Toronto	Canada	90	2.41
5th	INSERM	France	87	2.33
6th	Universidade de São Paulo	Brazil	80	2.15
7th	McMaster University	UK	79	2.12
8th	University College London	UK	78	2.09
9th	Brigham and Women's Hospital	USA	71	1.91
10th	Tehran University of Medical Sciences	Iran	63	1.69

Analysis of funding agencies

Table 3 presents information on the top ten funding agencies that have actively engaged in producing articles related to COVID-19 RCTs. The data show that these funding agencies collectively contributed 17.54% of the documents. Among the leading contributors, the *National Institutes of Health* provided funding for the highest number of articles ($n = 262$; 7.03%), followed by the *National Natural Science Foundation of China* ($n = 107$; 2.87%) and the *National Institute of Allergy and Infectious Diseases* ($n = 99$; 2.66%), as indicated in Table 3.

Table 3 The top ten funding agencies with the most publications related to COVID-19 RCTs

Ranking	Funding agencies	Country	No. of publication	%
1st	National Institutes of Health	USA	262	7.03
2nd	National Natural Science Foundation of China	China	107	2.87
3rd	National Institute of Allergy and Infectious Diseases	USA	99	2.66
4th	National Heart, Lung, and Blood Institute	USA	88	2.36
5th	Pfizer	USA	83	2.23
6th	Gilead Sciences	USA	79	2.12
6th	National Institute for Health and Care Research	UK	79	2.12
8th	National Center for Advancing Translational Sciences	USA	74	1.99
9th	Medical Research Council	UK	68	1.82
10th	Wellcome Trust	UK	66	1.77

Active journals

Table 4 shows details on the top ten journals that actively published articles related to COVID-19 RCTs. The data

Table 4 The top ten journals with the most publications related to COVID-19 RCTs

Ranking	Journal	No. of publica- tion	%	IF ¹
1st	Trials	173	4.64	2.728
2nd	BMJ Open	81	2.17	3.006
3rd	Plos One	73	1.96	3.752
4th	JAMA Network Open	53	1.42	13.353
4th	New England Journal of Medicine	53	1.42	176.079
6th	Medicine	52	1.40	1.817
7th	International Journal of Environmental Research and Public Health	50	1.34	4.614
8th	Eclinicalmedicine	47	1.26	17.033
8th	Scientific Reports	47	1.26	4.996
10th	Lancet Respiratory Medicine	46	1.23	102.642

¹Impact factor (IF) from Journal Citation Reports (Source Clarivate, 2022)

indicate that these funding agencies collectively contributed to 18.11% of the total published documents. Among the top ten journals, *trials* ($n = 173$, 4.64%), *BMJ Open* ($n = 81$, 2.17%), *Plos One* ($n = 73$, 1.96%) and *JAMA Network Open* ($n = 53$, 1.42%) are the most prominent, as shown in Table 4.

Analysis of citations

Based on citation analysis, the average number of times the retrieved articles were cited was 42.47, and they achieved an h-index of 162 with a total of 157,211 citations. Citations for these articles ranged from 0 to 7517, with 561 of them not having any citations and 238 receiving 100 or more citations. The ten most-cited articles on COVID-19 RCTs received a total of 37,324 citations. The citations ranged from 1459 to 7517 [78–87]. This information can be found in Table 5.

Co-occurrence analysis

A co-occurrence network was created based on how often terms appeared in article titles and abstracts to identify the most important research topics in the field of COVID-19 RCTs. Figure 2 shows the most common research topics in the field of COVID-19 RCTs in the past three years. VOSviewer analysis was used to search for terms in the titles and abstracts of 3,727 documents. The map was created with

Table 5 The top ten cited articles for publications related to COVID-19 RCTs

Ranking	Authors	Title	Year	Source title	Cited by
1st	Polack et al. [84]	“Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine”	2020	New England Journal of Medicine	7517
2nd	Horby et al. [83]	“Dexamethasone in hospitalized patients with covid-19”	2021	New England Journal of Medicine	5646
3rd	Baden et al. [78]	“Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine”	2021	New England Journal of Medicine	5051
4th	Beigel et al. [79]	“Remdesivir for the treatment of COVID-19—Final report”	2020	New England Journal of Medicine	4160
5th	Cao et al. [80]	“A trial of lopinavir-ritonavir in adults hospitalized with severe covid-19”	2020	New England Journal of Medicine	3553
6th	Gautret et al. [82]	“Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial”	2020	International Journal of Antimicrobial Agents	3452
7th	Voysey et al. [85]	“Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK”	2021	The Lancet	2726
8th	Wang et al. [87]	“Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial”	2020	The Lancet	2234
9th	Folegatti et al. [81]	“Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial”	2020	The Lancet	1526
10th	Walsh et al. [86]	“Safety and immunogenicity of two RNA-based covid-19 vaccine candidates”	2020	New England Journal of Medicine	1459




Fig. 2 Cluster map based on term analysis appearing in titles or abstracts. The size of the circle indicates the occurrences of the terms, and the different colors indicate the variety of clusters. The map was created using VOSviewer software version 1.6.19

259 terms out of 664,923 terms, which were categorized into four clusters with at least 100 appearances per term. The most common terms were related to (a) the safety and effectiveness of COVID-19 vaccines [78, 84, 85, 88–94] (yellow cluster), (b) mental health strategies to cope with the impact of the pandemic [95–99] (green cluster), (c) the use of monoclonal antibodies to treat COVID-19 patients [100–105] (red cluster), and (d) systematic reviews and meta-analyses of COVID-19 research [72, 106–114] (blue cluster). This approach helped us pinpoint the most pressing issues in COVID-19 research and monitor the field's growth. You can see the clusters in Fig. 2.

Future research direction analysis

Figure 3 in VOSviewer employs a distinctive color scheme that assigns a unique color to each term based on its average frequency in all the publications that were retrieved. The color scheme follows a pattern where yellow denotes the most recent occurrences, while blue signifies the earliest occurrences. Prior to 2021, the field primarily focused on examining the connection between the use of neutralizing monoclonal antibodies and the risk of hospital admission

and mortality in patients with COVID-19 and conducting systematic reviews and meta-analyses of randomized trials related to COVID-19. However, research on the "safety and immunogenicity of COVID-19 vaccines" and "mental health strategies to address the impact of COVID-19 on individuals' mental health" emerged more recently at the end of 2021 and beyond.

Discussion

The descriptive findings of the current study shed light on COVID-19-related RCTs. The aforementioned data shed light on numerous publications, prestigious journals, research topics, and collaborative networks. The current findings shed light on the primary research foci and directions for COVID-19. These insights can help researchers, policymakers, and funders make informed decisions and identify research gaps. In the current COVID-19 pandemic, due to the unprecedented global death toll [115], scientific research has a decisive impact on the prevention and control of the disease. Despite the relatively short period in which much of the scientific literature on this topic has been



Based on bibliometric analysis, the current results highlight the top countries and institutions in the main list. The base list refers to a series of journals widely recognized as the most prestigious and influential in this area. The current study reveals research productivity and country and institution influence. The top core list countries were high-income destination countries, including the US, UK, and Canada. It is not surprising that high-income countries rank high in bibliometric research studies because they have a strong research infrastructure, including funding, science and technology, and human resources [65–67, 116, 117]. Therefore,

The current investigation delineated four prominent research themes in RCTs and COVID-19 research by systematically analyzing terms and fields of research interest. The findings of this study revealed the most common terms in the scholarly literature and their prevalence in various publications. In particular, the theme of the safety and effectiveness of COVID-19 vaccines emerged as a prominent area of interest within current research. The current scientific consensus on the safety and effectiveness of COVID-19 vaccines has been established through extensive and rigorous clinical trials that show that these vaccines are highly effective in preventing infection with the SARS-CoV-2 virus and its associated disease, COVID-19 [118, 119]. Many large-scale studies in different populations have confirmed that COVID-19 vaccines have a

high degree of safety with a minimum risk of serious side effects [119, 120]. Furthermore, real-life data from vaccine deployments in many countries provide convincing evidence that vaccines can significantly reduce hospitalization, serious illness, and mortality rates associated with COVID-19 [84, 121, 122].

Mental health strategies to address the impact of the pandemic have been a highly discussed topic during the COVID-19 outbreak. The COVID-19 pandemic has profoundly impacted global mental health [123]. The disturbances caused by the pandemic have led to a widespread epidemic of anxiety, depression, and other mental health problems [124]. Mental health strategy tests have become important to address these challenges [125, 126]. Mental health strategies focus on evaluating interventions that aim to reduce the impact of the epidemic on mental health. These interventions include psychological interventions such as cognitive behavior therapy, online self-help interventions, and telepsychiatry [127, 128]. In addition, non-pharmacological interventions such as physical exercise and social support have also been studied [129]. The pandemic has affected different populations in different ways, and testing mental health strategies must take into account these differences. For example, first-line healthcare workers were disproportionately affected by the pandemic, and mental health strategy trials targeting this population were launched [130, 131].

Another hot topic is ‘the use of monoclonal antibodies to treat COVID-19 patients’. Although some vaccines have been developed and approved for emergency use, the emergence of new variants and the slow onset of vaccination in some regions have highlighted the need for effective treatment options [15]. One promising approach is the use of monoclonal antibodies to treat patients with COVID-19 [132]. Monoclonal antibodies are laboratory proteins that mimic the immune system's ability to fight harmful pathogen viruses such as severe acute respiratory syndrome coronavirus-2 [133]. They are specifically designed to target a specific antigen on the surface of a virus, in this case, the SARS-CoV-2 spike protein [134]. Several monoclonal antibodies against SARS-CoV-2 have been developed, including bamlanivimab, casirivimab, and imdevimab, which have received emergency approval from the US Food and Drug Administration [135, 136]. Clinical studies have revealed that monoclonal antibodies can reduce the risk of hospitalization and death in patients with COVID-19 who are not hospitalized and are at high risk of developing severe disease [137, 138].

Another current hot issue is “the systematic reviews and meta-analyses of RCTs related to COVID-19 research”. Systematic reviews and meta-analyses are frequent in medical research. Due to the rapid progress and amount of research productivity, these approaches are ideal for COVID-19

study. Systematic reviews and meta-analyses enhance clinical decision-making and public health policy by summarizing relevant research [139, 140]. Recent data indicate that most COVID-19 systematic reviews and meta-analyses are conducted in countries with high incomes, including the US, UK, and Canada [140]. This is expected since these countries have research infrastructures, funds, equipment, and qualified investigators [141, 142]. However, it should be noted that COVID-19 research concentrated on research from high-income countries could also be considered a limitation. This is because COVID-19 affects countries all over the world, including many low- and middle-income countries where resources and research infrastructure may be limited [143]. Therefore, researchers and policy makers must ensure that the results of COVID-19 research conducted in high-income countries are relevant to the global context [144, 145].

Based on the topic maps analyzed, it is evident that a significant number of scholarly works have been published that focus on two central themes related to the COVID-19 pandemic: the safety and efficacy of COVID-19 vaccines and mental health strategies aimed at mitigating the adverse impact of the pandemic on individuals' psychological well-being. In particular, these two themes have gained prominence in recent years; however, the COVID-19 outbreak has heightened their significance and urgency. Given the sustained effects of the pandemic and the persistent need for mental health support, it is probable that these topics will continue to be of paramount importance in the foreseeable future. Consequently, additional research efforts and focused attention are imperative to effectively address the novel challenges in these fields. Urgency, public interest, existing expertise, innovation potential, and collaboration all influence the prominence of research fields [146, 147]. Priority is often given to research fields that have the potential to offer innovative solutions to prevalent issues. Finding effective treatments and preventive measures is crucial in the case of COVID-19. The study shows that COVID-19 vaccines, mental health strategies, monoclonal antibodies, and systematic reviews were the most prevalent research topics. These areas directly address crucial pandemic aspects, such as vaccine development, mental health support, and therapeutic interventions [148–151]. In addition, research fields that foster collaboration and networking among researchers tend to expand more rapidly. Collaborative efforts can result in interdisciplinary insights and broader research outcomes. The study's co-occurrence analysis identified four clusters of COVID-19-related research areas. These clusters presumably represent collaborative networks of researchers working on specific topics, indicating that collaboration has shaped the research landscape [64, 152–154].

Future and clinical implications of the current study

By highlighting the disparities and considering the progression of research throughout this pandemic, potential implications for worldwide health research and application can be indicated as follows:

1. The study covers the most common COVID-19 RCT themes, including vaccinations, mental health, monoclonal antibodies, and systematic reviews. Data can help researchers, policymakers, and funders focus on the most important locations of pandemics.
2. Policymakers and funders can strategically allocate resources using this study. Identifying research groups such as mental health methods and monoclonal antibody treatments helps invest in pandemic research that could improve clinical results and public health.
3. Anticipated research directions recognize emerging research disciplines. Policymakers and funding organizations can use this evidence to anticipate trends and allocate resources to support research on COVID-19 and other challenges and opportunities.
4. The method can be used to identify research gaps in future pandemics and global health emergencies. By evaluating the strengths and shortcomings of the COVID-19 research response, the global health community can better manage and mitigate these outbreaks.

Strengths and limitations

This study represents the most comprehensive and up-to-date bibliometric analysis of COVID-19 RCTs available, providing valuable information for patients, therapists, and researchers. However, it is important to acknowledge several limitations. First, the study used the Scopus database exclusively to identify relevant articles, which is widely considered a reliable and comprehensive source in many academic fields but may have resulted in the omission of publications from other databases, such as PubMed and Web of Science [155–159]. Second, the study used a comprehensive list of keywords derived from previous literature reviews [59–62, 69–72], yet it is possible that some relevant keywords were overlooked, potentially leading to false negative results. Third, the study selected the ten most frequently cited articles, but the citation count is time dependent, and older papers are more likely to be cited, potentially biasing the selection of highly cited articles. Fourth, the study limited the search to terms related to COVID-19 RCTs in the title and abstract only, which may have excluded relevant articles that used these terms elsewhere in the text. Finally, the use

of Scopus data may not fully capture the research output of active institutions with multiple Scopus profiles or funding agencies identified by various names in published papers. Therefore, to minimize bias, it is essential to restrict data analysis related to the most active institutions and funding agencies to the results obtained from Scopus without any manipulation or merging.

Conclusions

This bibliometric analysis revealed that the research evidence available in recent years, especially last year, has steadily increased. The results conclude that the research on COVID-19 RCTs has been a collaborative effort between countries, institutions, and funding institutions. The United States, the United Kingdom, China, and Canada contributed the most to the publications. *Harvard Medical School*, *Oxford University*, and *Imperial College London* are the leading universities actively involved in the production of research articles. The *National Institutes of Health*, *China's National Natural Sciences Foundation*, and the *National Institutes of Allergy and Infectious Diseases* provide the highest funding for research articles. *Trials*, *BMJ Open*, *Plos One*, and *JAMA Network Open* are the most active journals that publish articles on COVID-19 RCTs. Co-occurrence analyses identified four main research areas: vaccine safety and effectiveness, mental health strategies, monoclonal antibody treatment, and systematic review and meta-analysis of COVID-19 RCTs. It is recommended that future research on COVID-19 RCTs continue to focus on these four areas. Collaborating with countries, institutions, and funding bodies should encourage support and funding for research in these fields. The most active journals should continue to publish research on these subjects. Continued research in these areas will provide valuable information contributing to global efforts to control and manage the COVID-19 epidemic. In the global health field, this study's implications highlight the importance of strategic research planning, collaboration, and data-driven decision-making. By acknowledging the achievements and gaps, the global health community can work more effectively to combat the ongoing pandemic and establish a solid foundation to address future health challenges.

Acknowledgements The author thanks An-Najah National University for all its administrative assistance during the implementation of the project. In addition, the author thanks Drs. Adham Abu Taha and Samah Al-Jabi for helping and validating the research strategy.

Author's contribution SZ, the sole author, read and approved the final manuscript.

Funding No support was received for conducting this study.

Data availability All data generated or analyzed during this study are included in this published article. In addition, other datasets used during the current study are available from the author on reasonable request (saedzyoud@yahoo.com).

Declarations

Competing interests The author declares that he has no competing interests.

Ethical approval As this is a bibliometric study, without human involvement, there was no need for ethical approval.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

References

1. Sachs JD, Karim SSA, Aknin L, et al. The Lancet Commission on lessons for the future from the COVID-19 pandemic. *Lancet*. 2022;400:1224–80. [https://doi.org/10.1016/S0140-6736\(22\)01585-9](https://doi.org/10.1016/S0140-6736(22)01585-9).
2. World Health Organization. WHO Coronavirus (COVID-19) Dashboard, <https://covid19.who.int/> (2023, accessed May 3 2023).
3. Leach M, MacGregor H, Scoones I, Wilkinson A. Post-pandemic transformations: how and why COVID-19 requires us to rethink development. *World Dev*. 2021;138: 105233. <https://doi.org/10.1016/j.worlddev.2020.105233>.
4. Park JJH, Mogg R, Smith GE, et al. How COVID-19 has fundamentally changed clinical research in global health. *Lancet Glob Health*. 2021;9:e711–20. [https://doi.org/10.1016/s2214-109x\(20\)30542-8](https://doi.org/10.1016/s2214-109x(20)30542-8).
5. U.S. Food and Drug Administration. FDA Guidance on Conduct of Clinical Trials of Medical Products During the COVID-19 Public Health Emergency, <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/fda-guidance-conduct-clinical-trials-medical-products-during-covid-19-public-health-emergency> (2021, accessed April 30 2023).
6. Wu H, Dai R, He P, et al. Characteristics analysis for clinical study design relating to COVID-19 based on the database of ClinicalTrials.gov. *Int J Infect Dis*. 2022;116:210–5. <https://doi.org/10.1016/j.ijid.2022.01.015>.
7. Mitchell EJ, Ahmed K, Breeman S, et al. It is unprecedented: trial management during the COVID-19 pandemic and beyond. *Trials*. 2020;21:784. <https://doi.org/10.1186/s13063-020-04711-6>.
8. Janiaud P, Hemkens LG, Ioannidis JPA. challenges and lessons learned from COVID-19 trials: Should we be doing clinical trials differently? *Can J Cardiol*. 2021;37:1353–64. <https://doi.org/10.1016/j.cjca.2021.05.009>.
9. Mainoli B, Machado T, Duarte GS, et al. Analysis of clinical and methodological characteristics of early COVID-19 treatment clinical trials: so much work, so many lost opportunities. *BMC Med Res Methodol*. 2021;21:42. <https://doi.org/10.1186/s12874-021-01233-w>.
10. Sathian B, Asim M, Banerjee I, et al. Impact of COVID-19 on clinical trials and clinical research: a systematic review. *Nepal J Epidemiol*. 2020;10:878–87. <https://doi.org/10.3126/nje.v10i3.31622>.
11. Greenhalgh T, Fisman D, Cane DJ, Oliver M, Macintyre CR. Adapt or die: how the pandemic made the shift from EBM to EBM+ more urgent. *BMJ Evid Based Med*. 2022;27:253–60. <https://doi.org/10.1136/bmjebm-2022-111952>.
12. Filip R, Gheorghita Puscaselu R, Anchidin-Norocel L, Dimian M, Savage WK. Global challenges to public health care systems during the COVID-19 pandemic: a review of pandemic measures and problems. *J Pers Med*. 2022. <https://doi.org/10.3390/jpm12081295>.
13. Park JJH, Decloedt EH, Rayner CR, Cotton M, Mills EJ. Clinical trials of disease stages in COVID 19: complicated and often misinterpreted. *Lancet Glob Health*. 2020;8:e1249–50. [https://doi.org/10.1016/s2214-109x\(20\)30365-x](https://doi.org/10.1016/s2214-109x(20)30365-x).
14. Thorlund K, Dron L, Park J, Hsu G, Forrest JI, Mills EJ. A real-time dashboard of clinical trials for COVID-19. *Lancet Digit Health*. 2020;2:e286–7. [https://doi.org/10.1016/s2589-7500\(20\)30086-8](https://doi.org/10.1016/s2589-7500(20)30086-8).
15. Wouters OJ, Shadlen KC, Salcher-Konrad M, et al. Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment. *Lancet*. 2021;397:1023–34. [https://doi.org/10.1016/S0140-6736\(21\)00306-8](https://doi.org/10.1016/S0140-6736(21)00306-8).
16. Emani VR, Goswami S, Nandanor D, Emani SR, Reddy NK, Reddy R. Randomised controlled trials for COVID-19: evaluation of optimal randomisation methodologies-need for data validation of the completed trials and to improve ongoing and future randomised trial designs. *Int J Antimicrob Agents*. 2021;57: 106222. <https://doi.org/10.1016/j.ijantimicag.2020.106222>.
17. Niknam Z, Jafari A, Golchin A, et al. Potential therapeutic options for COVID-19: an update on current evidence. *Eur J Med Res*. 2022;27:6. <https://doi.org/10.1186/s40001-021-00626-3>.
18. U.S. National Library of Medicine. A literature hub for tracking up-to-date scientific information about the 2019 novel Coronavirus, <https://www.ncbi.nlm.nih.gov/research/coronavirus/> (2023, accessed May 6 2023).
19. Hallas D, Spratling R, Fletcher J. Methodological analysis: randomized controlled trials for pfizer and moderna COVID-19 vaccines. *J Pediatr Health Care*. 2021;35:443–8. <https://doi.org/10.1016/j.pedhc.2021.04.001>.
20. Bauchner H, Fontanarosa PB. Randomized clinical trials and COVID-19: managing expectations. *JAMA*. 2020;323:2262–3. <https://doi.org/10.1001/jama.2020.8115>.
21. Wood L, Egger M, Gluud LL, et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. *BMJ*. 2008;336:601–5. <https://doi.org/10.1136/bmj.39465.451748.AD>.
22. Donthu N, Kumar S, Mukherjee D, Pandey N, Lim WM. How to conduct a bibliometric analysis: an overview and guidelines. *J Bus Res*. 2021;133:285–96. <https://doi.org/10.1016/j.jbusres.2021.04.070>.
23. Wallin JA. Bibliometric methods: pitfalls and possibilities. *Basic Clin Pharmacol Toxicol*. 2005;97:261–75. https://doi.org/10.1111/j.1742-7843.2005.pto_139.x.
24. Ninkov A, Frank JR, Maggio LA. Bibliometrics: methods for studying academic publishing. *Perspect Med Educ*. 2022;11:173–6. <https://doi.org/10.1007/s40037-021-00695-4>.
25. Ellegaard O, Wallin JA. The bibliometric analysis of scholarly production: How great is the impact? *Scientometrics*. 2015;105:1809–31. <https://doi.org/10.1007/s11192-015-1645-z>.

26. Thompson DF, Walker CK. A descriptive and historical review of bibliometrics with applications to medical sciences. *Pharmacotherapy*. 2015;35:551–9. <https://doi.org/10.1002/phar.1586>.
27. Robert C, Wilson CS. Thirty-year survey of bibliometrics used in the research literature of pain: analysis, evolution, and pitfalls. *Front Pain Res (Lausanne)*. 2023;4:1071453. <https://doi.org/10.3389/fpain.2023.1071453>.
28. Guo K, Li J, Li X, Huang J, Zhou Z. Emerging trends and focus on the link between gut microbiota and type 1 diabetes: a bibliometric and visualization analysis. *Front Microbiol*. 2023;14:1137595. <https://doi.org/10.3389/fmicb.2023.1137595>.
29. Morante-Carballo F, Montalván-Burbano N, Quiñonez-Barzola X, Jaya-Montalvo M, Carrión-Mero P. What do we know about water scarcity in semi-arid zones? A global analysis and research trends. *Water*. 2022;14:2685. <https://doi.org/10.3390/w14172685>.
30. Yang S, Hao S, Ye H, Zhang X. Global research on the crosstalk between intestinal microbiome and colorectal cancer: a visualization analysis. *Front Cell Infect Microbiol*. 2023;13:1083987. <https://doi.org/10.3389/fcimb.2023.1083987>.
31. Zhao J, Kong Y, Xiang Y, Yang J. The research landscape of the quality of life or psychological impact on gynecological cancer patients: a bibliometric analysis. *Front Oncol*. 2023;13:1115852. <https://doi.org/10.3389/fonc.2023.1115852>.
32. Deng R, Wang M, Song Y, Shi Y. A bibliometric analysis on the research trend of exercise and the gut microbiome. *Microorganisms*. 2023;11:903. <https://doi.org/10.3390/microorganisms11040903>.
33. Cabanillas-Lazo M, Quispe-Vicuna C, Barja-Ore J, et al. A 10-year bibliometric analysis of global research on gut microbiota and parkinson's disease: characteristics, impact, and trends. *Biomed Res Int*. 2022;2022:4144781. <https://doi.org/10.1155/2022/4144781>.
34. Zhang T, Zhang B, Ma X, et al. Research trends in the field of the gut-brain interaction: functional dyspepsia in the spotlight - an integrated bibliometric and science mapping approach. *Front Neurosci*. 2023;17:1109510. <https://doi.org/10.3389/fnins.2023.1109510>.
35. Yang Z, Ma Y, Bi W, Tang J. Exploring the research landscape of COVID-19-induced olfactory dysfunction: a bibliometric study. *Front Neurosci*. 2023;17:1164901. <https://doi.org/10.3389/fnins.2023.1164901>.
36. Yeung AWK. The revived interest in Ageusia research during the COVID-19 pandemic: a bibliometric analysis. *Life (Basel)*. 2023;13:1062. <https://doi.org/10.3390/life13041062>.
37. Hu W, Xu Y. The published trend of studies on COVID-19 and dietary supplements: bibliometric analysis. *Front Immunol*. 2022;13:1065724. <https://doi.org/10.3389/fimmu.2022.1065724>.
38. Xavier-Santos D, Padilha M, Fabiano GA, et al. Evidences and perspectives of the use of probiotics, prebiotics, synbiotics, and postbiotics as adjuvants for prevention and treatment of COVID-19: a bibliometric analysis and systematic review. *Trends Food Sci Technol*. 2022;120:174–92. <https://doi.org/10.1016/j.tifs.2021.12.033>.
39. Guleid FH, Oyando R, Kabia E, Mumbi A, Akech S, Barasa E. A bibliometric analysis of COVID-19 research in Africa. *BMJ Glob Health*. 2021;6: e005690.
40. Mayta-Tovalino F. Bibliometric analyses of global scholarly output in dentistry related to COVID-19. *J Int Soc Prev Community Dent*. 2022;12:100–8. https://doi.org/10.4103/jispcd.JISPCD_294_21.
41. Falagas ME, Pitsouni EI, Malietzis GA, Pappas G. Comparison of pubmed, scopus, web of science, and google scholar: strengths and weaknesses. *FASEB J*. 2008;22:338–42. <https://doi.org/10.1096/fj.07-9492LSF>.
42. Kulkarni AV, Aziz B, Shams I, Busse JW. Comparisons of citations in web of science, scopus, and google scholar for articles published in general medical journals. *JAMA*. 2009;302:1092–6. <https://doi.org/10.1001/jama.2009.1307>.
43. Mongeon P, Paul-Hus A. The journal coverage of Web of Science and Scopus: a comparative analysis. *Scientometrics*. 2016;106:213–28. <https://doi.org/10.1007/s11192-015-1765-5>.
44. Vera-Baceta M-A, Thelwall M, Kousha K. Web of science and scopus language coverage. *Scientometrics*. 2019;121:1803–13. <https://doi.org/10.1007/s11192-019-03264-z>.
45. Aksnes DW, Sivertsen G. A criteria-based assessment of the coverage of scopus and web of science. *J Data Inf Sci*. 2019;4:1–21. <https://doi.org/10.2478/jdis-2019-0001>.
46. Archambault É, Vignola-Gagné É, Côté G, Larivière V, Gingras Y. Benchmarking scientific output in the social sciences and humanities: The limits of existing databases. *Scientometrics*. 2006;68:329–42. <https://doi.org/10.1007/s11192-006-0115-z>.
47. Grant MJ, Booth A. A typology of reviews: an analysis of 14 review types and associated methodologies. *Health Info Libr J*. 2009;26:91–108. <https://doi.org/10.1111/j.1471-1842.2009.00848.x>.
48. Levac D, Colquhoun H, O'Brien KK. Scoping studies: advancing the methodology. *Implement Sci*. 2010;5:69. <https://doi.org/10.1186/1748-5908-5-69>.
49. Møller AM, Myles PS. What makes a good systematic review and meta-analysis? *Br J Anaesth*. 2016;117:428–30. <https://doi.org/10.1093/bja/aew264>.
50. Sweileh WM. A bibliometric analysis of health-related literature on natural disasters from 1900 to 2017. *Health Res Policy Syst*. 2019;17:18. <https://doi.org/10.1186/s12961-019-0418-1>.
51. Pearson A. Balancing the evidence: incorporating the synthesis of qualitative data into systematic reviews. *JBIR Reports*. 2004;2:45–64. <https://doi.org/10.1111/j.1479-6988.2004.00008.x>.
52. Aromataris E, Pearson A. The systematic review: an overview. *Am J Nurs*. 2014;114:53–8. <https://doi.org/10.1097/01.NAJ.0000444496.24228.2c>.
53. Aromataris E, Riitano D. Constructing a search strategy and searching for evidence. A guide to the literature search for a systematic review. *Am J Nurs*. 2014;114:49–56. <https://doi.org/10.1097/01.NAJ.0000446779.99522.f6>.
54. Porritt K, Gomersall J, Lockwood C. JBI's systematic reviews: study selection and critical appraisal. *Am J Nurs*. 2014;114:47–52. <https://doi.org/10.1097/01.naj.0000450430.97383.64>.
55. Munn Z, Peters MDJ, Stern C, Tufanaru C, McArthur A, Aromataris E. Systematic review or scoping review? Guidance for authors when choosing between a systematic or scoping review approach. *BMC Med Res Methodol*. 2018;18:143. <https://doi.org/10.1186/s12874-018-0611-x>.
56. Anderson S, Allen P, Peckham S, Goodwin N. Asking the right questions: scoping studies in the commissioning of research on the organisation and delivery of health services. *Health Res Policy Syst*. 2008;6:7. <https://doi.org/10.1186/1478-4505-6-7>.
57. Colquhoun HL, Levac D, O'Brien KK, et al. Scoping reviews: time for clarity in definition, methods, and reporting. *J Clin Epidemiol*. 2014;67:1291–4. <https://doi.org/10.1016/j.jclinepi.2014.03.013>.
58. Khalil H, Peters M, Godfrey CM, McInerney P, Soares CB, Parker D. An evidence-based approach to scoping reviews. *Worldviews Evid Based Nurs*. 2016;13:118–23. <https://doi.org/10.1111/wvn.12144>.
59. Rogers JP, Chesney E, Oliver D, et al. Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic. *Lancet Psychiatry*. 2020;7:611–27. [https://doi.org/10.1016/S2215-0366\(20\)30203-0](https://doi.org/10.1016/S2215-0366(20)30203-0).

60. Mao R, Qiu Y, He JS, et al. Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis. *Lancet Gastroenterol Hepatol*. 2020;5:667–78. [https://doi.org/10.1016/S2468-1253\(20\)30126-6](https://doi.org/10.1016/S2468-1253(20)30126-6).
61. Chmielewska B, Barratt I, Townsend R, et al. Effects of the COVID-19 pandemic on maternal and perinatal outcomes: a systematic review and meta-analysis. *Lancet Glob Health*. 2021;9:e759–72. [https://doi.org/10.1016/S2214-109X\(21\)00079-6](https://doi.org/10.1016/S2214-109X(21)00079-6).
62. Ling RR, Ramanathan K, Tan FL, et al. Myopericarditis following COVID-19 vaccination and non-COVID-19 vaccination: a systematic review and meta-analysis. *Lancet Respir Med*. 2022;10:679–88. [https://doi.org/10.1016/S2213-2600\(22\)00059-5](https://doi.org/10.1016/S2213-2600(22)00059-5).
63. Zyoud SH, Shakhshir M, Koni A, Shahwan M, Jairoun AA, Al-Jabi SW. Olfactory and gustatory dysfunction in COVID-19: a global bibliometric and visualized analysis. *Ann Otol Rhinol Laryngol*. 2022. <https://doi.org/10.1177/00034894221082735>.
64. Zyoud SH, Al-Jabi SW. Mapping the situation of research on coronavirus disease-19 (COVID-19): a preliminary bibliometric analysis during the early stage of the outbreak. *BMC Infect Dis*. 2020;20:561. <https://doi.org/10.1186/s12879-020-05293-z>.
65. Zyoud SH, Al-Jabi SW, Koni A, Shakhshir M, Shahwan M, Jairoun AA. Mapping the landscape and structure of global research on nutrition and COVID-19: visualization analysis. *J Health Popul Nutr*. 2022;41:25. <https://doi.org/10.1186/s41043-022-00304-y>.
66. Zyoud SH, Koni A, Al-Jabi SW, et al. Current global research landscape on COVID-19 and cancer: bibliometric and visualization analysis. *World J Clin Oncol*. 2022;13:835–47. <https://doi.org/10.5306/wjco.v13.i10.835>.
67. Zyoud SH, Al-Jabi SW, Shahwan MJ, Jairoun AA. Global research production pertaining to gastrointestinal involvement in COVID-19: a bibliometric and visualised study. *World J Gastrointest Surg*. 2022;14:494–505. <https://doi.org/10.4240/wjgs.v14.i5.494>.
68. Al-Jabi SW. Current global research landscape on COVID-19 and depressive disorders: bibliometric and visualization analysis. *World J Psychiatry*. 2021;11:253–64. <https://doi.org/10.5498/wjp.v11.i6.253>.
69. Martins-Filho PR, Ferreira LC, Heimfarth L, Araújo AAS, Quintans-Júnior LJ. Efficacy and safety of hydroxychloroquine as pre- and post-exposure prophylaxis and treatment of COVID-19: a systematic review and meta-analysis of blinded, placebo-controlled, randomized clinical trials. *Lancet Reg Health Am*. 2021;2: 100062. <https://doi.org/10.1016/j.lana.2021.100062>.
70. Amstutz A, Speich B, Mentre F, et al. Effects of remdesivir in patients hospitalised with COVID-19: a systematic review and individual patient data meta-analysis of randomised controlled trials. *Lancet Respir Med*. 2023. [https://doi.org/10.1016/S2213-2600\(22\)00528-8](https://doi.org/10.1016/S2213-2600(22)00528-8).
71. Pormohammad A, Zarei M, Ghorbani S, et al. Efficacy and safety of COVID-19 vaccines: a systematic review and meta-analysis of randomized clinical trials. *Vaccines (Basel)*. 2021;9:467. <https://doi.org/10.3390/vaccines9050467>.
72. Varikasuvu SR, Thangappazham B, Vykunta A, et al. COVID-19 and vitamin D (Co-VIVID study): a systematic review and meta-analysis of randomized controlled trials. *Expert Rev Anti Infect Ther*. 2022;20:907–13. <https://doi.org/10.1080/14787210.2022.2035217>.
73. Karasneh RA, Al-Azzam SI, Alzoubi KH, Hawamdeh SS, Sweileh WM. Global research trends of health-related publications on ramadan fasting from 1999 to 2021: a bibliometric analysis. *J Relig Health*. 2022;61:3777–94. <https://doi.org/10.1007/s10943-022-01573-x>.
74. Sweileh WM. Substandard and falsified medical products: bibliometric analysis and mapping of scientific research. *Global Health*. 2021;17:114. <https://doi.org/10.1186/s12992-021-00766-5>.
75. Sweileh WM. Global research activity on mathematical modeling of transmission and control of 23 selected infectious disease outbreak. *Global Health*. 2022;18:4. <https://doi.org/10.1186/s12992-022-00803-x>.
76. van Eck NJ, Waltman L. Software survey: VOSviewer, a computer program for bibliometric mapping. *Scientometrics*. 2010;84:523–38. <https://doi.org/10.1007/s11192-009-0146-3>.
77. van Eck NJ, Waltman L. Citation-based clustering of publications using CitNetExplorer and VOSviewer. *Scientometrics*. 2017;111:1053–70. <https://doi.org/10.1007/s11192-017-2300-7>.
78. Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. *N Engl J Med*. 2021;384:403–16. <https://doi.org/10.1056/NEJMoa2035389>.
79. Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of Covid-19 - final report. *N Engl J Med*. 2020;383:1813–26. <https://doi.org/10.1056/NEJMoa2007764>.
80. Cao B, Wang Y, Wen D, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe covid-19. *N Engl J Med*. 2020;382:1787–99. <https://doi.org/10.1056/NEJMoa2001282>.
81. Folegatti PM, Ewer KJ, Aley PK, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. *Lancet*. 2020;396:467–78. [https://doi.org/10.1016/S0140-6736\(20\)31604-4](https://doi.org/10.1016/S0140-6736(20)31604-4).
82. Gautret P, Lagier JC, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. *Int J Antimicrob Agents*. 2020;56: 105949. <https://doi.org/10.1016/j.ijantimicag.2020.105949>.
83. Horby P, Lim WS, Emberson JR, et al. Dexamethasone in hospitalized patients with Covid-19. *N Engl J Med*. 2021;384:693–704. <https://doi.org/10.1056/NEJMoa2021436>.
84. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. *N Engl J Med*. 2020;383:2603–15. <https://doi.org/10.1056/NEJMoa2034577>.
85. Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. *Lancet*. 2021;397:99–111. [https://doi.org/10.1016/S0140-6736\(20\)32661-1](https://doi.org/10.1016/S0140-6736(20)32661-1).
86. Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. *N Engl J Med*. 2020;383:2439–50. <https://doi.org/10.1056/NEJMoa2027906>.
87. Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. *Lancet*. 2020;395:1569–78. [https://doi.org/10.1016/S0140-6736\(20\)31022-9](https://doi.org/10.1016/S0140-6736(20)31022-9).
88. Thomas SJ, Moreira ED Jr, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months. *N Engl J Med*. 2021;385:1761–73. <https://doi.org/10.1056/NEJMoa2110345>.
89. Moreira ED Jr, Kitchin N, Xu X, et al. Safety and efficacy of a third dose of BNT162b2 Covid-19 vaccine. *N Engl J Med*. 2022;386:1910–21. <https://doi.org/10.1056/NEJMoa2200674>.
90. Heath PT, Galiza EP, Baxter DN, et al. Safety and efficacy of NVX-CoV2373 Covid-19 vaccine. *N Engl J Med*. 2021;385:1172–83. <https://doi.org/10.1056/NEJMoa2107659>.
91. Frenck RW Jr, Klein NP, Kitchin N, et al. Safety, immunogenicity, and efficacy of the BNT162b2 Covid-19 vaccine in adolescents. *N Engl J Med*. 2021;385:239–50. <https://doi.org/10.1056/NEJMoa2107456>.

92. Wu S, Huang J, Zhang Z, et al. Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial. *Lancet Infect Dis.* 2021;21:1654–64. [https://doi.org/10.1016/s1473-3099\(21\)00396-0](https://doi.org/10.1016/s1473-3099(21)00396-0).
93. Munro APS, Feng S, Janani L, et al. Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial. *Lancet Infect Dis.* 2022;22:1131–41. [https://doi.org/10.1016/s1473-3099\(22\)00271-7](https://doi.org/10.1016/s1473-3099(22)00271-7).
94. Stuart ASV, Shaw RH, Liu X, et al. Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial. *Lancet.* 2022;399:36–49. [https://doi.org/10.1016/s0140-6736\(21\)02718-5](https://doi.org/10.1016/s0140-6736(21)02718-5).
95. Malboeuf-Hurtubise C, Leger-Goodes T, Mageau GA, et al. Philosophy for children and mindfulness during COVID-19: results from a randomized cluster trial and impact on mental health in elementary school students. *Prog Neuropsychopharmacol Biol Psychiatr.* 2021;107: 110260. <https://doi.org/10.1016/j.pnpbp.2021.110260>.
96. Fiol-DeRoque MA, Serrano-Ripoll MJ, Jimenez R, et al. A mobile phone-based intervention to reduce mental health problems in health care workers during the COVID-19 pandemic (PsyCovidApp): randomized controlled trial. *JMIR Mhealth Uhealth.* 2021;9: e27039. <https://doi.org/10.2196/27039>.
97. Beauchamp MR, Hulteen RM, Ruissen GR, et al. Online-delivered group and personal exercise programs to support low active older adults' mental health during the COVID-19 pandemic: randomized controlled trial. *J Med Internet Res.* 2021;23: e30709. <https://doi.org/10.2196/30709>.
98. Temple JR, Baumler E, Wood L, Guillot-Wright S, Torres E, Thiel M. The impact of the COVID-19 pandemic on adolescent mental health and substance use. *J Adolesc Health.* 2022;71:277–84. <https://doi.org/10.1016/j.jadohealth.2022.05.025>.
99. Blackett JW, Sun Y, Purpura L, et al. Decreased gut microbiome tryptophan metabolism and serotonergic signaling in patients with persistent mental health and gastrointestinal symptoms after COVID-19. *Clin Transl Gastroenterol.* 2022;13: e00524. <https://doi.org/10.14309/ctg.0000000000000524>.
100. Salama C, Han J, Yau L, et al. Tocilizumab in patients hospitalized with covid-19 pneumonia. *N Engl J Med.* 2021;384:20–30. <https://doi.org/10.1056/NEJMoa2030340>.
101. Montgomery H, Hobbs FDR, Padilla F, et al. Efficacy and safety of intramuscular administration of tixagevimab-cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial. *Lancet Respir Med.* 2022;10:985–96. [https://doi.org/10.1016/S2213-2600\(22\)00180-1](https://doi.org/10.1016/S2213-2600(22)00180-1).
102. Levin MJ, Ustianowski A, De Wit S, et al. Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for prevention of Covid-19. *N Engl J Med.* 2022;386:2188–200. <https://doi.org/10.1056/NEJMoa2116620>.
103. ACTIV-3—Therapeutics for Inpatients with COVID-19 (TICO) Study Group. Tixagevimab-cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, double-blind, phase 3 trial. *Lancet Respir Med.* 2022;10:972–984. [https://doi.org/10.1016/S2213-2600\(22\)00215-6](https://doi.org/10.1016/S2213-2600(22)00215-6).
104. Recovery Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. *Lancet.* 2021;397:1637–45. [https://doi.org/10.1016/S0140-6736\(21\)00676-0](https://doi.org/10.1016/S0140-6736(21)00676-0).
105. Gupta A, Gonzalez-Rojas Y, Juarez E, et al. Early treatment for Covid-19 with SARS-CoV-2 neutralizing antibody sotrovimab. *N Engl J Med.* 2021;385:1941–50. <https://doi.org/10.1056/NEJMo2107934>.
106. Gupta T, Kannan S, Kalra B, Thakkar P. Systematic review and meta-analysis of randomised controlled trials testing the safety and efficacy of convalescent plasma in the treatment of coronavirus disease 2019 (COVID-19): evidence-base for practise and implications for research. *Transfus Med.* 2021;31:409–20. <https://doi.org/10.1111/tme.12803>.
107. Medeiros KS, Costa APF, Sarmento ACA, Freitas CL, Goncalves AK. Side effects of COVID-19 vaccines: a systematic review and meta-analysis protocol of randomised trials. *BMJ Open.* 2022;12: e050278. <https://doi.org/10.1136/bmjopen-2021-050278>.
108. Lai CC, Wang YH, Chen KH, Chen CH, Wang CY. The clinical efficacy and safety of anti-viral agents for non-hospitalized patients with COVID-19: a systematic review and network meta-analysis of randomized controlled trials. *Viruses.* 2022. <https://doi.org/10.3390/v14081706>.
109. Rawat D, Roy A, Maitra S, Gulati A, Khanna P, Baidya DK. Vitamin C and COVID-19 treatment: a systematic review and meta-analysis of randomized controlled trials. *Diabetes Metab Syndr.* 2021;15: 102324. <https://doi.org/10.1016/j.dsx.2021.102324>.
110. Sharif N, Alzahrani KJ, Ahmed SN, Dey SK. Efficacy, immunogenicity and safety of COVID-19 vaccines: a systematic review and meta-analysis. *Front Immunol.* 2021;12: 714170. <https://doi.org/10.3389/fimmu.2021.714170>.
111. Chong WH, Saha BK, Tan CK. Clinical outcomes of routine awake prone positioning in COVID-19 patients: a systematic review and meta-analysis of randomized controlled trials. *Prague Med Rep.* 2022;123:140–65. <https://doi.org/10.14712/23362936.2022.14>.
112. Kamel AM, Monem MSA, Sharaf NA, Magdy N, Farid SF. Efficacy and safety of azithromycin in Covid-19 patients: a systematic review and meta-analysis of randomized clinical trials. *Rev Med Virol.* 2022;32: e2258. <https://doi.org/10.1002/rmv.2258>.
113. Pormohammad A, Zarei M, Ghorbani S, et al. Efficacy and safety of COVID-19 vaccines: a systematic review and meta-analysis of randomized clinical trials. *Vaccines (Basel).* 2021. <https://doi.org/10.3390/vaccines9050467>.
114. Asimwe IG, Pushpakom SP, Turner RM, Kolamunnage-Dona R, Jorgensen AL, Pirmohamed M. Cardiovascular drugs and COVID-19 clinical outcomes: a systematic review and meta-analysis of randomized controlled trials. *Br J Clin Pharmacol.* 2022;88:3577–99. <https://doi.org/10.1111/bcp.15331>.
115. Chang D, Chang X, He Y, Tan KJK. The determinants of COVID-19 morbidity and mortality across countries. *Sci Rep.* 2022;12:5888. <https://doi.org/10.1038/s41598-022-09783-9>.
116. Zyoud SH. Analyzing and visualizing global research trends on COVID-19 linked to sustainable development goals. *Environ Dev Sustain.* 2022. <https://doi.org/10.1007/s10668-022-02275-w>.
117. Zyoud SH, Shakhshir M, Koni A, Shahwan M, Jairoun AA, Al-Jabi SW. Olfactory and gustatory dysfunction in COVID-19: a global bibliometric and visualized analysis. *Ann Otol Rhinol Laryngol.* 2023;132:164–72. <https://doi.org/10.1177/00034894221082735>.
118. Hodgson SH, Mansatta K, Mallett G, Harris V, Emary KRW, Pollard AJ. What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2. *Lancet Infect Dis.* 2021;21:e26–35. [https://doi.org/10.1016/s1473-3099\(20\)30773-8](https://doi.org/10.1016/s1473-3099(20)30773-8).
119. Chirico F, Teixeira da Silva JA, Tsigaris P, Sharun K. Safety & effectiveness of COVID-19 vaccines: a narrative review. *Indian J*

- Med Res. 2022;155:91–104. https://doi.org/10.4103/ijmr.IJMR_474_21.
120. Liu Q, Qin C, Liu M, Liu J. Effectiveness and safety of SARS-CoV-2 vaccine in real-world studies: a systematic review and meta-analysis. *Infect Dis Poverty*. 2021;10:132. <https://doi.org/10.1186/s40249-021-00915-3>.
 121. Anderson EJ, Roupael NG, Widge AT, et al. Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. *N Engl J Med*. 2020;383:2427–38. <https://doi.org/10.1056/NEJMoa2028436>.
 122. Gui Y-Z, Li X-N, Li J-X, et al. Safety and immunogenicity of a modified COVID-19 mRNA vaccine, SW-BIC-213, as a heterologous booster in healthy adults: an open-labeled, two-centered and multi-arm randomised, phase 1 trial. *EBioMedicine*. 2023. <https://doi.org/10.1016/j.ebiom.2023.104586>.
 123. Santomauro DF, Mantilla Herrera AM, Shadid J, et al. Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic. *Lancet*. 2021;398:1700–12. [https://doi.org/10.1016/S0140-6736\(21\)02143-7](https://doi.org/10.1016/S0140-6736(21)02143-7).
 124. Clemente-Suarez VJ, Martinez-Gonzalez MB, Benitez-Agudelo JC, et al. The impact of the COVID-19 pandemic on mental disorders: a critical review. *Int J Environ Res Public Health*. 2021. <https://doi.org/10.3390/ijerph181910041>.
 125. Pierce M, McManus S, Hope H, et al. Mental health responses to the COVID-19 pandemic: a latent class trajectory analysis using longitudinal UK data. *Lancet Psychiatry*. 2021;8:610–9. [https://doi.org/10.1016/S2215-0366\(21\)00151-6](https://doi.org/10.1016/S2215-0366(21)00151-6).
 126. Magnusdottir I, Lovik A, Unnarsdottir AB, et al. Acute COVID-19 severity and mental health morbidity trajectories in patient populations of six nations: an observational study. *Lancet Public Health*. 2022;7:e406–16. [https://doi.org/10.1016/S2468-2667\(22\)00042-1](https://doi.org/10.1016/S2468-2667(22)00042-1).
 127. Rutkowska A. Telemedicine interventions as an attempt to improve the mental health of populations during the COVID-19 pandemic—a narrative review. *Int J Environ Res Public Health*. 2022. <https://doi.org/10.3390/ijerph192214945>.
 128. Song J, Jiang R, Chen N, et al. Self-help cognitive behavioral therapy application for COVID-19-related mental health problems: a longitudinal trial. *Asian J Psychiatr*. 2021;60: 102656. <https://doi.org/10.1016/j.ajp.2021.102656>.
 129. Ai X, Yang J, Lin Z, Wan X. Mental health and the role of physical activity during the COVID-19 pandemic. *Front Psychol*. 2021;12: 759987. <https://doi.org/10.3389/fpsyg.2021.759987>.
 130. De Kock JH, Latham HA, Leslie SJ, et al. A rapid review of the impact of COVID-19 on the mental health of healthcare workers: implications for supporting psychological well-being. *BMC Public Health*. 2021;21:104. <https://doi.org/10.1186/s12889-020-10070-3>.
 131. Akinin LB, Andretti B, Goldszmidt R, et al. Policy stringency and mental health during the COVID-19 pandemic: a longitudinal analysis of data from 15 countries. *Lancet Public Health*. 2022;7:e417–26. [https://doi.org/10.1016/S2468-2667\(22\)00060-3](https://doi.org/10.1016/S2468-2667(22)00060-3).
 132. Hwang YC, Lu RM, Su SC, et al. Monoclonal antibodies for COVID-19 therapy and SARS-CoV-2 detection. *J Biomed Sci*. 2022;29:1. <https://doi.org/10.1186/s12929-021-00784-w>.
 133. Vita S, Rosati S, Ascoli Bartoli T, et al. Monoclonal antibodies for pre- and postexposure prophylaxis of COVID-19: review of the literature. *Pathogens*. 2022. <https://doi.org/10.3390/pathogens11080882>.
 134. Huang Y, Yang C, Xu XF, Xu W, Liu SW. Structural and functional properties of SARS-CoV-2 spike protein: potential anti-virus drug development for COVID-19. *Acta Pharmacol Sin*. 2020;41:1141–9. <https://doi.org/10.1038/s41401-020-0485-4>.
 135. Abani O, Abbas A, Abbas F, et al. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. *The Lancet*. 2022;399:665–76. [https://doi.org/10.1016/S0140-6736\(22\)00163-5](https://doi.org/10.1016/S0140-6736(22)00163-5).
 136. Haddad F, Dokmak G, Karaman R. A comprehensive review on the efficacy of several pharmacologic agents for the treatment of COVID-19. *Life*. 2022;12:1758.
 137. A. CTIV-3-Therapeutics for Inpatients with COVID-19 Study Group. Tixagevimab-cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, double-blind, phase 3 trial. *Lancet Respir Med* 2022;10:972–984. [https://doi.org/10.1016/S2213-2600\(22\)00215-6](https://doi.org/10.1016/S2213-2600(22)00215-6).
 138. Razonable RR, Pawlowski C, O'Horo JC, et al. Casirivimab-Imdevimab treatment is associated with reduced rates of hospitalization among high-risk patients with mild to moderate coronavirus disease-19. *EClinicalMedicine*. 2021;40: 101102. <https://doi.org/10.1016/j.eclinm.2021.101102>.
 139. Nassar M, Nso N, Alfahawy M, et al. Current systematic reviews and meta-analyses of COVID-19. *World J Virol*. 2021;10:182–208. <https://doi.org/10.5501/wjv.v10.i4.182>.
 140. Borges do Nascimento IJ, O'Mathuna DP, von Groote TC, et al. Coronavirus disease (COVID-19) pandemic: an overview of systematic reviews. *BMC Infect Dis*. 2021;21:525. <https://doi.org/10.1186/s12879-021-06214-4>.
 141. Sitthi-Amorn C, Somrongthong R. Strengthening health research capacity in developing countries: a critical element for achieving health equity. *BMJ*. 2000;321:813–7. <https://doi.org/10.1136/bmj.321.7264.813>.
 142. Amerson RM, Strang CW. Addressing the challenges of conducting research in developing countries. *J Nurs Scholarsh*. 2015;47:584–91. <https://doi.org/10.1111/jnu.12171>.
 143. Gashaw T, Hagos B, Sisay M. Expected impacts of COVID-19: considering resource-limited countries and vulnerable population. *Front Public Health*. 2021;9: 614789. <https://doi.org/10.3389/fpubh.2021.614789>.
 144. Gupta M, Wahl B, Adhikari B, et al. The need for COVID-19 research in low- and middle-income countries. *Glob Health Res Policy*. 2020;5:33. <https://doi.org/10.1186/s41256-020-00159-y>.
 145. Singh JA, Bandewar SV, Bukusi EA. The impact of the COVID-19 pandemic response on other health research. *Bull World Health Organ*. 2020;98:625–31. <https://doi.org/10.2471/blt.20.257485>.
 146. Ploeg J, Wong ST, Hassani K, et al. Contextual factors influencing the implementation of innovations in community-based primary health care: the experience of 12 Canadian research teams. *Prim Health Care Res Dev*. 2019;20: e107. <https://doi.org/10.1017/s1463423619000483>.
 147. Kruk ME, Gage AD, Arseneault C, et al. High-quality health systems in the Sustainable Development Goals era: time for a revolution. *Lancet Glob Health*. 2018;6:e1196–252. [https://doi.org/10.1016/s2214-109x\(18\)30386-3](https://doi.org/10.1016/s2214-109x(18)30386-3).
 148. Holmes EA, O'Connor RC, Perry VH, et al. Multidisciplinary research priorities for the COVID-19 pandemic: a call for action for mental health science. *Lancet Psychiatry*. 2020;7:547–60. [https://doi.org/10.1016/s2215-0366\(20\)30168-1](https://doi.org/10.1016/s2215-0366(20)30168-1).
 149. Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. *Nat Rev Microbiol*. 2023;21:133–46. <https://doi.org/10.1038/s41579-022-00846-2>.
 150. Hanney SR, Wooding S, Sussex J, Grant J. From COVID-19 research to vaccine application: Why might it take 17 months not 17 years and what are the wider lessons? *Health Res Policy Syst*. 2020;18:61. <https://doi.org/10.1186/s12961-020-00571-3>.
 151. Forman R, Shah S, Jeurissen P, Jit M, Mossialos E. COVID-19 vaccine challenges: What have we learned so far and what

- remains to be done? *Health Policy*. 2021;125:553–67. <https://doi.org/10.1016/j.healthpol.2021.03.013>.
152. Thavorn J, Gowanit C, Muangsin V, Muangsin N. Collaboration network and trends of global coronavirus disease research: a scientometric analysis. *IEEE Access*. 2021;9:45001–16. <https://doi.org/10.1109/access.2021.3066450>.
 153. Zhao Y, Liu L, Zhang C. Is coronavirus-related research becoming more interdisciplinary? A perspective of co-occurrence analysis and diversity measure of scientific articles. *Technol Forecast Soc Change*. 2022;175: 121344. <https://doi.org/10.1016/j.techfore.2021.121344>.
 154. Andersen N, Bramness JG, Lund IO. The emerging COVID-19 research: dynamic and regularly updated science maps and analyses. *BMC Med Inform Decis Mak*. 2020;20:309. <https://doi.org/10.1186/s12911-020-01321-9>.
 155. Ogunsakin RE, Ebenezer O, Jordaan MA, Shapi M, Ginindza TG. Mapping scientific productivity trends and hotspots in remdesivir research publications: a bibliometric study from 2016 to 2021. *Int J Environ Res Public Health*. 2022. <https://doi.org/10.3390/ijerph19148845>.
 156. Rojas-Montesino E, Mendez D, Espinosa-Parrilla Y, Fuentes E, Palomo I. Analysis of scientometric indicators in publications associated with healthy aging in the world, Period 2011–2020. *Int J Environ Res Public Health*. 2022. <https://doi.org/10.3390/ijerph19158988>.
 157. Obaideen K, Abu Shihab KH, Madkour MI, Faris ME. Seven decades of Ramadan intermittent fasting research: Bibliometrics analysis, global trends, and future directions. *Diabetes Metab Syndr*. 2022;16: 102566. <https://doi.org/10.1016/j.dsx.2022.102566>.
 158. Trejo-Castro AI, Carrion-Alvarez D, Martinez-Torteya A, Rangel-Escareno C. A bibliometric review on gut microbiome and Alzheimer's disease between 2012 and 2021. *Front Aging Neurosci*. 2022;14: 804177. <https://doi.org/10.3389/fnagi.2022.804177>.
 159. Sweileh WM. Patient satisfaction with nursing care: a bibliometric and visualization analysis (1950–2021). *Int J Nurs Pract*. 2022. <https://doi.org/10.1111/ijn.13076>.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.